Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.

Antiviral therapy - 1 Jan 2010

Price Huw, Asboe David, Pozniak Anton, Gazzard Brian, Fearnhill Esther, Pillay Deenan, Dunn David

Abstract excerpt

BACKGROUND: There is conflicting evidence on specific reverse transcriptase inhibitors to which the N348I mutation in the connection domain of HIV type-1 reverse transcriptase confers resistance. Here, we examined associations between the emergence of N348I and antiretroviral history in a large clinical database. METHODS: We analysed 5,353 resistance tests (that were sequenced beyond codon 348) among 2,266...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines
Share to Cyclopropanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nevirapine

Share to Organophosphonates

Share to Stavudine

Share to Tenofovir

Share to Zidovudine

Source

Identifiers

PMID: 20386075
DOI: 10.3851/IMP1511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.PMID 20386075Read ↗

Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.Semantic proximity Read ↗

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.Semantic proximity Read ↗

HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy.Semantic proximity Read ↗

Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase InhibitorsSemantic proximity Read ↗

N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.Semantic proximity Read ↗

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutationsSemantic proximity Read ↗

[Studying on the prevalence and mutation pattern of N348I which related to the resistance of HIV-1].Semantic proximity Read ↗

Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.Semantic proximity Read ↗

Connection domain mutations in treatment-experienced patients in the OPTIMA trial.Semantic proximity Read ↗

Selection of Mutations in HIV-1 Nucleocapsid and Integrase in Individuals Living with HIV Experiencing Virologic Failure After Initiating or Switching to Tenofovir-Lamivudine-DolutegravirSemantic proximity Read ↗

Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility.Semantic proximity Read ↗

Using machine learning and big data to explore the drug resistance landscape in HIVSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.